Bioventix (BVXP) has announced its 6-month interim results to end-December 2024, reporting 1H25 group revenues of £6.73m, broadly in line with the prior period (+1% YoY) and a reflection of the maturity of the markets that BVXP’s antibody portfolio services. Management’s reference to “steady” troponin-related revenues echoes commentary from the FY24 results, which suggested that troponin antibody sales within the diagnostic setting may be approaching their peak. However, we believe there remains ....
